Total Payments
$12,156
2024 Payments
$10,519
Companies
7
Transactions
25
Medicare Patients
836
Medicare Billing
$137,063
Payment Breakdown by Category
Consulting$8,979 (73.9%)
Research$1,333 (11.0%)
Travel$1,243 (10.2%)
Food & Beverage$601.90 (5.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,979 | 4 | 73.9% |
| Unspecified | $1,333 | 12 | 11.0% |
| Travel and Lodging | $1,243 | 3 | 10.2% |
| Food and Beverage | $601.90 | 6 | 5.0% |
Payments by Type
General
$10,823
13 transactions
Research
$1,333
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $9,207 | 8 | $0 (2024) |
| Shire North American Group Inc | $1,333 | 12 | $0 (2019) |
| BeiGene USA, Inc. | $675.00 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $525.00 | 1 | $0 (2024) |
| SOBI, INC | $200.00 | 1 | $0 (2024) |
| Genentech USA, Inc. | $109.65 | 1 | $0 (2019) |
| Mallinckrodt Enterprises LLC | $106.48 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,519 | 10 | GENZYME CORPORATION ($9,119) |
| 2021 | $88.39 | 1 | GENZYME CORPORATION ($88.39) |
| 2019 | $1,549 | 14 | Shire North American Group Inc ($1,333) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 11/26/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: Oncology | ||||||
| 08/07/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/09/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $7,578.50 | General |
| 03/09/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $750.38 | General |
| 03/09/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $265.84 | General |
| 03/09/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $226.66 | General |
| 03/09/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $200.04 | General |
| 03/09/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $75.07 | General |
| 03/09/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $22.27 | General |
| 10/05/2021 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $88.39 | General |
| Category: Hematology | ||||||
| 10/10/2019 | Mallinckrodt Enterprises LLC | CELLEX/XTS PHOTOPHERESIS SYSTEM (Device) | Food and Beverage | In-kind items and services | $106.48 | General |
| Category: CRITICAL CARE | ||||||
| 05/10/2019 | Genentech USA, Inc. | HEMLIBRA (Biological) | Food and Beverage | In-kind items and services | $109.65 | General |
| Category: Hematology | ||||||
| 03/28/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $206.31 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/28/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $199.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/28/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $199.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/28/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $60.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/28/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $44.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/28/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/27/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $60.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/27/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $44.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/27/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/27/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/26/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $130.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
| 03/20/2019 | Shire North American Group Inc | — | — | Cash or cash equivalent | $315.60 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA ATTP TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 SHP655 ADMINISTERED IN ADDITION TO STANDARD OF CARE SOC TREATMENT | Shire North American Group Inc | $1,333 | 12 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 186 | 265 | $100,892 | $23,852 |
| 2022 | 9 | 244 | 411 | $144,516 | $36,218 |
| 2021 | 7 | 202 | 416 | $144,061 | $37,923 |
| 2020 | 8 | 204 | 442 | $153,014 | $39,070 |
Total Patients
836
Total Services
1,534
Medicare Billing
$137,063
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 36514 | Mechanical separation of plasma from opening blood | Facility | 2020 | 17 | 42 | $26,418 | $3,568 | 13.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 19 | 47 | $11,186 | $2,972 | 26.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 20 | 33 | $4,408 | $2,288 | 51.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 23 | 38 | $5,540 | $2,184 | 39.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 13 | 14 | $4,970 | $1,312 | 26.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 16 | 19 | $2,488 | $804.60 | 32.3% |
About Dr. Brian Carney, M.D
Dr. Brian Carney, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2013. The National Provider Identifier (NPI) number assigned to this provider is 1255779252.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Carney, M.D has received a total of $12,156 in payments from pharmaceutical and medical device companies, with $10,519 received in 2024. These payments were reported across 25 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($8,979).
As a Medicare-enrolled provider, Carney has provided services to 836 Medicare beneficiaries, totaling 1,534 services with total Medicare billing of $137,063. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 06/12/2013
- Last Updated 07/01/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255779252
Products in Payments
- BRUKINSA (Drug) $675.00
- Truqap (Drug) $525.00
- VONJO (Drug) $200.00
- HEMLIBRA (Biological) $109.65
- CELLEX/XTS PHOTOPHERESIS SYSTEM (Device) $106.48
- CABLIVI (Biological) $88.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795